

RTOG Report to ATC Advisory Committee



Radiation Therapy
Oncology Group



Radiation Therapy Oncology Group



THE UNIVERSITY OF TEXAS
MD ANDERSON
CANCER CENTER
Making Cancer History™

AMERICAN ASSOCIATION OF
PHYSICISTS IN MEDICINE



Radiological Physics Center

RCET

University of Florida
Radiation Oncology

QARC

Quality Assurance
Review Center



Radiation Therapy
Oncology Group

RTOG Headquarters Provides

- Medical Dosimetrist QA review of advanced technology clinical trials using the ATC web-based remote review tools (RRT) which utilizes a secure web server;
- Dose-volume analysis of case data in RTOG protocols;
- RTOG Headquarters staff arranges for the ongoing monthly (1st Wednesday of each month) ATC conference calls, case review calls ongoing, as needed and protocol specific issues calls biweekly Friday mornings;
- A review of all advanced technology protocols that are developed through the ATC to help ensure uniformity of guidelines;
- Their expertise in maintaining and improving in the current electronic link between the RTOG's clinical trial database and the ITC's treatment planning and verification (TPV) database.



Radiation Therapy
Oncology Group

ATC Review Workstation at RTOG HQ's in Philadelphia, PA





Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol RTOG-9803 Dose-Volume Analysis QA Review for:

Patient Initials: RE Case #: 93
Group: 1 Dose Level: 2 Rx Dose: 72 (Gy) (See Appendix I)

A. TARGET VOLUME ANALYSIS

Target	Volume (cc)	Percent Volume Receiving > 0.93 Rx Dose(D1)	ICRU Ref Dose (Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)	Coverage Score
PTV1	162.32	100% % > 42.78 Gy		72.8	48.0	66.7	1
PTV2	29.02	100% % > 66.96 Gy	72.18	72.8	70.2	71.9	1

Target Volume Coverage Score: 1 : $V_{0.93\text{RxD}} = 100\%$, 2 : $95\% \leq V_{0.93\text{RxD}} < 100\%$, 3 : $V_{0.93\text{RxD}} < 95\%$

Was Patient Stratified Correctly (Group 1:PTV2 < 75 cc; Group 2: PTV2 ≥ 75 cc)? Yes No

B. DOSE HETEROGENEITY(DH) And CONFORMITY

	Conformity Index*	Dose Heterogeneity	Dose Heterogeneity Score
PTV1		1.011	1
PTV2	.310		

Dose Heterogeneity (Max Dose/Rx dose): 1 : $DH < 1.03$, 2 : $1.03 \leq DH \leq 1.10$, 3 : $DH > 1.10$

C. NORMAL STRUCTURE ANALYSIS (See appendix II for standard structure names)

Normal Tissue	Volume (cc)	% Vol ≥ Ref Dose (D1)	Ref Dose (D1) (Gy)	Max Dose (Gy)	Mean Dose (Gy)
Ipsilateral Cerebrum	508.7	42.5	45.0	72.8	39.9
Contralateral Cerebrum	525.82	16.0	45.0	72.4	22.5
Ipsilateral Optic Nerve	1.06	0	50.0	4.2	1.9
Contralateral Optic Nerve	1.36	0	50.0	4.2	1.7
Ipsilateral Globe	9.43	0	45.0	5.0	1.1
Contralateral Globe	11.6	0	45.0	2.8	1.1
Cerebellum	93.19	0	45.0	23.2	12.8
Brainstem	22.23	0	50.0	29.2	16.8
Spinal Cord	12.96	0	47.0	12.2	1.8
Optic Chiasm	2.12	0	50.0	16.8	7.2
Unspecified Tissues	4785.3	.2	58.9	69.8	2.9

Reviewed by: [Signature] Date: 12/12/02

After completing this form please FAX to the ITC: (314)747-5423.

***CONFORMITY INDEX:**

$$CF(\text{cover factor}) = \frac{\# \text{ points } \geq \text{prescription dose in PTV}}{\text{Total } \# \text{ points in PTV}}$$

$$SF(\text{spill factor}) = 1 - \frac{\# \text{ points } \geq \text{prescription dose not in PTV}}{\text{Total of all points } \geq \text{prescription dose}}$$

$$CI(\text{conformity index}) = CF \times SF$$

Perfect CI = 1.000



Image-guided Therapy Center

Protocol: 9803 Case: 0063
Plan Description: composite plan (Plan ID: totalhomo) Plan Date: Mon Sep 9 14:26

Calculation Volume Size: Width(x) 16.9(cm) x Depth(y) 14.9(cm) x Height(z) 20.4(cm) [81 x 81 x 89]
Center: X = 0.4, Y = -1.6, Z = 1.2 SITE: Brain - Supratentorial (Excl. Cerebrum) MD: ldsh

Beam # (Field): . . .	1 (_____)	2 (_____)	3 (_____)	4 (_____)
Description:	PA(B1)	LT LAT(B2)	AP(B3)	RT
Machine ID:	6MVXRAYS	6MVXRAYS	6MVXRAYS	1
Setup Distance: . . .	100.0 cm SAD	100.0 cm SAD	100.0 cm SAD	100.
Isocenter Depth: . . .	ODI(_____) 10.6 cm	ODI(_____) 7.4 cm	ODI(_____) 7.6 cm	ODI(_____) 7.6 cm
Isocenter Coord: . . .	0.6, -0.0, 2.3 cm	0.6, -0.0, 2.3 cm	0.6, -0.0, 2.3 cm	0.6, -0.0, 2.3 cm
Entry Point:	0.6, 0.0, -8.2 cm	8.0, 0.0, 2.3 cm	0.6, 0.0, 9.9 cm	-6.5, 0.0, 2.3 cm
Coll. Width(cone): . .	X1: 5.3 cm X2: 6.3 cm	X1: 9.0 cm X2: 3.0 cm	X1: 5.3 cm X2: 6.3 cm	X1: 5.3 cm X2: 6.3 cm
Coll. Length(cone): .	Y1: 3.0 cm Y2: 8.5 cm	Y1: 5.3 cm Y2: 6.3 cm	Y1: 8.5 cm Y2: 3.0 cm	Y1: 8.5 cm Y2: 3.0 cm
Collimator Angle: . .	270 degrees	180 degrees	270 degrees	180
Couch Angle:	180 degrees	180 degrees	180 degrees	180
Head/Foot Orient: . .	Head to Gantry	Head to Gantry	Head to Gantry	Head to Gantry
Gantry Angle:	360 degrees	90 degrees	180 degrees	270
Rotation Arc:	x x x	x x x	x x x	x x x
Comp Filter Used: . . .	NO COMPENSATOR			
Bolus Used:	NO BOLUS USED	NO BOLUS USED	NO BOLUS USED	NO BOLUS USED
Wedge(Normal):	30W degree (Filt)	45W degree (Filt)	45W degree (Filt)	15W degree (Filt)
Wedge Orientation: . .	Heel RIGHT	Heel RIGHT	Heel RIGHT	Heel RIGHT
ICRU Ref Pt (cGy): . .	448 TD	1267 TD	1267 TD	
Films Link/Aligned: . .	_____	_____	_____	_____





Radiation Therapy
Oncology Group


Image-guided Therapy Center

PROTOCOL: 9803

CASE: 0093

STRUCTURE: PTV2

Remote Review Tool



Plan ID	% Vol >= D1 (66.96 Gy)	% Vol >= Dref (66.9 Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)
totalhomo	100.0	100.0	72.8	70.2	71.9

Calculated: Tue Dec 3 10:19:51 2002 (olddump.dat)

Printed Mon Apr 14 14:57:14 CDT 2003

[Close window](#)



Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol RTOG-9803 Dose-Volume Analysis QA Review for:

Patient Initials: RE Case #: 93
Group: 1 Dose Level: 2 Rx Dose: 72 (Gy) (See Appendix I)

A. TARGET VOLUME ANALYSIS

Target	Volume (cc)	Percent Volume Receiving > 0.93 Rx Dose(D1)	ICRU Ref Dose (Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)	Coverage Score
PTV1	162.32	100% % > 42.78 Gy		72.8	48.0	66.7	1
PTV2	29.02	100% % > 66.96 Gy	72.18	72.8	70.2	71.9	1

Target Volume Coverage Score: 1 : $V_{0.93\text{RxD}} = 100\%$, 2 : $95\% \leq V_{0.93\text{RxD}} < 100\%$, 3 : $V_{0.93\text{RxD}} < 95\%$

Was Patient Stratified Correctly (Group 1:PTV2 < 75 cc; Group 2: PTV2 ≥ 75 cc)? Yes No

B. DOSE HETEROGENEITY(DH) And CONFORMITY

	Conformity Index*	Dose Heterogeneity	Dose Heterogeneity Score
PTV1		1.011	1
PTV2	.310		

Dose Heterogeneity (Max Dose/Rx dose): 1 : $DH < 1.03$, 2 : $1.03 \leq DH \leq 1.10$, 3 : $DH > 1.10$

C. NORMAL STRUCTURE ANALYSIS (See appendix II for standard structure names)

Normal Tissue	Volume (cc)	% Vol ≥ Ref Dose (D1)	Ref Dose (D1) (Gy)	Max Dose (Gy)	Mean Dose (Gy)
Ipsilateral Cerebrum	508.7	42.5	45.0	72.8	39.9
Contralateral Cerebrum	525.82	16.0	45.0	72.4	22.5
Ipsilateral Optic Nerve	1.06	0	50.0	4.2	1.9
Contralateral Optic Nerve	1.36	0	50.0	4.2	1.7
Ipsilateral Globe	9.43	0	45.0	5.0	1.1
Contralateral Globe	11.6	0	45.0	2.8	1.1
Cerebellum	93.19	0	45.0	23.2	12.8
Brainstem	22.23	0	50.0	29.2	16.8
Spinal Cord	12.96	0	47.0	12.2	1.8
Optic Chiasm	2.12	0	50.0	16.8	7.2
Unspecified Tissues	4785.3	.2	58.9	69.8	2.9

Reviewed by: [Signature] Date: 12/12/02

After completing this form please FAX to the ITC: (314)747-5423.

***CONFORMITY INDEX:**

$$CF(\text{cover factor}) = \frac{\# \text{ points } \geq \text{prescription dose in PTV}}{\text{Total } \# \text{ points in PTV}}$$

$$SF(\text{spill factor}) = 1 - \frac{\# \text{ points } \geq \text{prescription dose not in PTV}}{\text{Total of all points } \geq \text{prescription dose}}$$

$$CI(\text{conformity index}) = CF \times SF$$

Perfect CI = 1.000



Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol RTOG-0319 Dose-Volume Analysis QA Review for : Univ. of Colorado Health Sciences

Pt. Initials M. M. Case #: 0014 0319c0014
 Group: 1 Dose Level: 38.5 Rx Dose: 38.5 (Gy)

A. TARGET VOLUME ANALYSIS

Target	Volume (cc)	Percent Volume Receiving ≥ 0.95 Rx Dose(D1)		ICRU Ref Dose (Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)	Coverage Score
PTV_EVAL	269.31	98.6	36.5	38.53	39.5	33.5	38.2	2

Target Volume Coverage Score: 1 : $V_{0.95RxD} = 100\%$, 2 : $95\% \leq V_{0.95RxD} < 100\%$, 3 : $V_{0.95RxD} < 95\%$

Number of Beams Used	8
----------------------	---

B. DOSE HETEROGENEITY(DH) And CONFORMITY

	Conformity Index*	Dose Heterogeneity	Dose Heterogeneity Score
PTV_EVAL	----	1.026	1

Dose Heterogeneity (Max Dose/Rx dose): 1 : $DH \leq 1.10$, 2 : $1.10 < DH \leq 1.20$, 3 : $DH > 1.20$

C. NORMAL STRUCTURE ANALYSIS (See appendix II for standard structure names)

Normal Tissue	Volume (cc)	% Vol \geq Ref Dose (D1)	Ref Dose (D1) (Gy)	Max Dose (Gy)	Mean Dose (Gy)
Ipsilateral Lung	1314.5	10.4	11.6	36.1	6.2
Contralateral Lung	1479.1	0	1.9	.6	.1
Ipsilateral Breast	1717.4	55.0/9.4	19.25/38.5	39.5	21.3
Contralateral Breast	1779.6	0	1.2	2.2	0
Thyroid	2.50	0	1.2	.3	.2
Heart	409.76	7.2	1.9	9.6	.7
Unspecified Tissue	14053	----	----	37.5	.9

Reviewed by: Bernadine	Date: 3/4/04
------------------------	--------------

After completing this form please FAX to the ITC: (314)747-5423.

***CONFORMITY INDEX:**

$$CF(\text{cover factor}) = \frac{\# \text{ points } \geq \text{prescription dose in PTV}}{\text{Total } \# \text{ points in PTV}}$$

$$SF(\text{spill factor}) = 1 - \frac{\# \text{ points } \geq \text{prescription dose not in PTV}}{\text{Total of all points } \geq \text{prescription dose}}$$

$$CI(\text{conformity index}) = CF \times SF$$

Perfect CI = 1.000

0319DVareview

Rev1.0Sep22.2003





Radiation Therapy
Oncology Group

RTOG Headquarters Provides (cont.)

RTOG Protocols supported by the ATC (as of March 29, 2004)

- 9 Studies (6 Active / 3 closed, data analysis continues)
 - RTOG 94-06: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy for Adenocarcinoma of the Prostate
 - 54 institutions credentialed; 1084 patients registered to study (study closed, data analysis continues)
 - RTOG 93-11: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with Inoperable NSCLC
 - 26 institutions credentialed; 180 patients registered to study (study closed, data analysis continues)
 - RTOG 98-03: Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme
 - 46 institutions credentialed; 210 patients registered to study (study closed, data analysis continues)



Radiation Therapy
Oncology Group

RTOG Headquarters Provides (cont.)

RTOG Protocols supported by the ATC (as of March 29, 2004) (cont.)

- RTOG H-0022: Phase I/II Study of Conformal And Intensity Modulated Irradiation for Oropharyngeal Cancer
 - 17 institutions credentialed; 38 patients registered to study; Target Accrual – 64
- RTOG L-0117: Phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable, non-small cell lung cancer
 - 36 institutions credentialed; 17 patients registered to study; Target Accrual – 64
- RTOG P-0126: Phase III randomize study of high dose 3DCRT/IMRT versus standard dose 3DCRT/IMRT in patients treated for localized prostate cancer
 - 86 institutions credentialed; 234 patients registered to study; Target Accrual – 1520



Radiation Therapy
Oncology Group

RTOG Headquarters Provides (cont.)

RTOG Protocols supported by the ATC (as of March 29, 2004) (cont.)

- RTOG 0225: Phase I/II Study of Conformal And Intensity Modulated Irradiation for Nasopharyngeal Cancer
 - 17 institutions credentialed; 15 patients registered to study; Target Accrual – 64
- RTOG 0232: Phase III Comparing Combined External Beam Radiation & Transperineal Interstitial Permanent Brachytherapy with Brachytherapy alone
 - 20 institutions credentialed; 28 patients registered to study; Target Accrual – 1520
- RTOG 0319: Phase I/II to Evaluate 3DCRT Irradiation Confined to Region of the Lumpectomy Cavity for Stage I/IIA Breast Carcinoma.
 - 24 institutions credentialed; 35 patients registered to study; Target Accrual – 46



Radiation Therapy
Oncology Group

RTOG Headquarters Provides (cont.)


Pending RTOG Protocols (ATC Resources Requested/Committed)

- 5 Studies
 - RTOG 0236: Phase II Extracranial Stereotactic Radioablation in Treatment of Patients with Medically Inoperable Stage in NSCLC.
 - RTOG 0238: A Phase I/II Study of Gross Tumor Volume Definition with or without Pet Fusion for Patients with Non-Small Cell Lung Carcinoma.
 - RTOG 0245: Phase I/II Highly Conformal Radiation Therapy for Patients with Unresectable Liver Metastases.
 - RTOG 0321: Phase I/II Prostate: High Dose Brachytherapy and External Beam.
 - RTOG 0413: Phase III Study of Whole Breast RT versus Partial Breast Irradiation.



Radiation Therapy
Oncology Group

RTOG 0232 Prostate – Brachytherapy Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0232



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Radiation Oncologist, M.D.
Institution – CTSU
Address
City, State, Zip Code

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for prostate brachytherapy and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG-0232 – A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma has been successfully met.

You are now approved to enter patients onto RTOG Prostate Implant Protocol 0232. A change in Radiation Oncologist, Physicist, treatment planning system, nuclide or seed model will require recredentialing by the RPC and/or ITC.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
Dosimetrist
RTOG Randomization
ITC
RPC
CTSU



Radiation Therapy
Oncology Group

Credentialed Institutions

RTOG – 0019 (14 Institutions Credentialed)

RTOG – 0232 (20 Institutions Credentialed)

RTOG Inst. #	RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys	Dry Run Sub. fTC	Dry Run Approval
RTOG Protocol P-0019									
	2619	U of Utah	isostar	5/9/2001	Gregory Patton	Jim Rankin	MMS-Variseed		
	2215	Roswell Park	uromed	5/21/2001	Michael Kuettel	Matthew Podgorsak	Theraplan Plus		
	1675	LDS Hosp	6711	10/1/2001	R. Jeffrey Lee	David Mathes	MMS-Variseed		
	1866	Methodist, Peoria	6711	6/19/2001	Revathi Swaminathan	Mohamed Ali	Focus		
	2613	Univ. of Rochester	6711	9/7/2001	Ralph Brasacchio	Yan Yu	RTek Piper (Home Grown)		
	2120	Queens Hosp	6711	7/16/2001	John Lederer	Ed Price	MMS-Variseed		
	1034	York Hosp (XRT done @ Apple Hill)	6711	7/16/2001	Amit Shah	Rick Raver	MMS-Variseed		
	1744	MD Anderson	6711	9/25/2001	Deborah Kuban	Ann Lawyer	MMS-Variseed		
	1714	London Regional	6711	12/20/2001	Varugar Venkatesan	Craig Lewis	Theraplan Plus		
	1788	McGuire VA	6711	3/7/2002	Michael Hagan	Nirmal Sakthi	MMS-Variseed		
	2740	Wilford Hall	6711	4/29/2002	Barry Gardner	Tarrance Harms, Minghong Wang	MMS-Variseed		
	1788	McGuire VA	Pd 200	6/12/2002	Michael Hagan	Nirmal Sakthi	MMS-Variseed		
	2182	Research Med Ctr	6711, Pd 200	6/17/2002	John Shetdon	Charles L. Smith	MMS-Variseed		
	1775	Mary Bird Perkins	IoGold	9/27/2002	Sheldon A. Johnson	Angela Stam	MMS-Variseed		
ACOSOG Protocol Z0070									
	2434	St. Luke's, Chesterfield, MO	Pd200, 6711	5/31/2002	David Butler, Karen Halverson	Abel Cheng	CMS-Focus		
	2271	Norfolk General, Norfolk, VA	Pd200	6/7/2002	Mark Shaves	Alex Gray	MMS-Variseed		
	2621	U-Wash, Seattle	6711	7/18/2002	Ken Russell	Mark Phillips	Prowess		
	1269	Cleveland Clinic	6711	8/14/2002	Jay Ciezki	Allan Wilkinson	MMS-Variseed		
	2100	Princess Margaret Hospital	6711, IoGold	8/23/2002	Michael McLean	Ivan Yeung	MMS-Variseed		
	1218	Central Arkansas Radiation Therapy Institute	6711	9/19/2002	Xiang Gao, Ann W. Maners	Dale Campbell	MMS-Variseed		
	1580	Hotel-Dieu de Quebec, Quebec	6711	9/19/2002	Eric Vigneault	Luc Beaulieu	Theraplan Plus		
	2110	Providence Hospital, Southfield, MI	6711	10/31/2002	Patrick McLaughlin	Vrinda Narayana	UM Plan		
	2100	Princess Margaret Hospital	Draximage LS-1	11/14/2002	Michael McLean	Ivan Yeung	MMS-Variseed		
	1427	Fletcher Allen (U-Vermont)	6711	12/10/2002	Peter Swift	Marleen Moore, David Desantis	MMS-Variseed		
	1823	Memorial-Sloan Kettering	6711	12/3/2002	Michael Zelefsky	Gil Cohen	Interplant iPAS		
RTOG Protocol P-0232									
	2650	Vanderbilt	I-plant	5/5/2003	Ming Teng	Charles Coffey, Bob Aus	Rosess		
	7718	Univ. of TX, San Antonio (Can. Ther. Res. Ctr)	IoGold, prostaseed, Pd200, pdgold, best pd	5/16/2003	Bradley Prestidge	William Bice	Home Grown and Variseed		
	5922	Mary Bird Perkins		7/18/2003	Sheldon A. Johnson	Angela Stam	Varian Variseed		
	3401	Roswell Park Cancer Institute		8/6/2003	Michael Kuettel	Matthew Podgorsak	Varian Variseed		
	2102	Washington University Medical Center		7/18/2003	Jeff Michalski		Varian Variseed		
	2687	Wake Forest University Baptist Med. Ctr.		9/4/2003	W. Robert Lee	Allan deGuzman	Varian Variseed		
	1518	1011 Akron City Hospital		9/29/2003	Michael Seider	Stanley Phillips	Varian Variseed		
	2501	1675 LDS Hospital		10/27/2003	R. J. Lee, M.D.	David Mathes	Varian Variseed		
	0137	2700 Washoe Medical Center		11/4/2003	Lawrence Dardick, M.D.	Richard Erickson, M.S.	Varian Variseed		
	5803	2805 South Suburban Oncology Center		11/14/2003	H. Joseph Barthold, M.D.	Sheri Weintraub, M.S.	Varian Variseed		
	7501	Cross Cancer Institute		11/14/2003	John Pedersen, M.D.	Ron Sioboda, Ph.D.	Varian Variseed		
	0152	Hospital of St. Raphael		11/18/2003	Joseph Cardinale, M.D.	Per Halvorsen, M.S.	Varian Variseed		
CTSU		Memorial Medical Center		12/5/2003	Francis Cardinale, M.D. Thomas Shanahan, M.D.	Randy Maxey, M.S.	Varian Variseed		
	2215	Princess Margaret Hospital		12/31/2003	Michael McLean, M.D. Seth Rosenthal, MD David Ilnstadt, MD	Ivan Yeung	Varian Variseed		
	6201	Radiological Associates of Sacramento			Mark Leibenhaut, MD	Miriam Lambert, Ph.D.	Varian Variseed		
	5301	2120 Queen's Medical Center in Honolulu		2/2/2004	John L. Lederer, M.D.	Edwin Price, Ph.D.	Amersham model 6711		
	0629	York Cancer Center, Wellspan		2/11/2004	Amit Shah, M.D.	Jadwiga B. Wojcicka, Ph.D.	Varian Variseed		
	9610	McKay Dee Hospital Center		2/12/2004	Gary Whipple, M.D.	Mark Arnfield, Ph.D.	Varian Variseed		
	5702	University of Maryland Medical Systems		2/16/2004	William Regine, M.D.	Mehrdad Sarfaraz, Ph.D.	Variseed		
	3701	1021 Allegheny General Hospital		3/15/2004	Russell Fuhrer, M.D.	Mark Johnson, M.S.	Varian Variseed		



Radiation Therapy
Oncology Group

Credentialed Institutions


RTOG – 9805 (43 Institutions Credentialed)

RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys.	Dry Run Sub. ITC	Dry Run Approval
RTOG Protocol 98-05								
2588	Univ of Chicago	6711	6/11/1999	Jaishanker Nautiyal	Franca Kuchnir	Silicon Graphics (Home Grown)		
2687	Wake Forest Univ (Bowman Gray)	6711	12/3/1999	W. Robert Lee	Allen deGuzman	MMS-Variseed		
1131	Bridgeport Hosp	6711	1/15/1999	Paul Berger	David Wishko	MMS-Variseed		
1786	Mayo/Jacksonville	6711	9/30/1998	Steven Buskirk	Christopher Serago	Pinnacle		
2536	Toronto Sunnybrook	6711	10/20/1998	Gerard Morton	William Que	MMS-Variseed		
2388	St. John, Detroit	6711	12/3/1998	Jwong Ling/Kenny Rhee	Walter Nikesch	Focus		
1076	Washington Univ	6711	12/3/1998	Jeff Michalski	Sasa Mutic	MMS-Variseed	3/14/2003	
1463	Geisinger	6711	1/15/1999	Omar Yumen	Rafael Yankelevich	MMS-Variseed		
2719	West Michigan	6711	12/3/1998	James Wheeler	Richard Mueller	MMS-Variseed		
1527	Wayne State	6711	1/15/1999	Paul Chuba/Jeffrey Forman	Mark Yudelev	Nucletron		
1276	St. Mary, Milwaukee	6711	2/12/1999	Carl Olson	John Whitton	MMS-Variseed		
1449	Fox Chase	6711	12/3/1998	Eric Horwitz	Tim Schultheiss/Raj Mitra	Plato		
2340	Spartanburg	6711	6/14/1999	Patricia Griffin	David Vassy	MMS-Variseed		
2015	Northwestern, Chicago	6711	4/20/1999	John Kalapurakal	V. Sathiaselalan/Cynthia Thomason	Prowess		
1834	Mercy Hosp, Pittsburgh	6711	4/20/1999	Michael Dougherty	Dan Pavord	Multidata DSS		
2582	Univ of Alabama	6711	12/20/1999	Robert Kim/John Fiveash	Prem Pareek	Prowess		
1313	Cross Cancer Inst. (U-Alberta)	6711	4/20/1999	John Pedersen	Ron Sloboda	Home Grown		
2704	Waukesha Memorial	6711	6/11/1999	Wingate Clapper	Katherine Albano	Prowess		
1557	Holmes Regional	6711	9/2/1999	David Grissell	Mary Ellen Masterson-McGary	Prowess		
				Khurshid Ahmad/Young Kim/				
2448	St. Mary's, Saginaw	6711	4/29/1999	Michael Cappelli	Jacek Wierzbicki	Prowess/Pinnacle		
1853	Roger Maris (Fargo)	6711	6/14/1999	Robert Arusell	John Pfund	MMS-Variseed		
2274	Kaweah Delta	6711	11/30/1999	John Lee	Don Hess	MMS-Variseed		
2323	Southeastern Wisc	6711	9/2/1999	James Taylor	Armin Langenegger	MMS-Variseed		
1423	Firelands Community	6711	9/2/1999	G. Phillip Engeler	Michael Ohm/Andrew Schneider	Prowess		
1254	Christ Hosp, Cincinnati	6711	6/23/1999	William Barrett	Steven Lukes	Theraplan Plus		
1900	Montefiore, New York	6711	3/15/2000	Chandon Guha	Doracy Fontena	Prowess		
1396	Ellis Fischel	6711	10/27/1999	Steve Westgate	William Kennedy	Pinnacle		
1894	Mobile Infirmary	6711	12/7/1999	John Russell	Michael Williams/Kim Flurry	Theraplan Plus		
2100	Princess Margaret	6711	1/12/2000	Juanita Crook	Phil Leung	MMS-Variseed		
1785	Mayo Clinic	6711	9/2/1999	Tomas Pisansky	Robert Kline	Theraplan Plus		
2597	Univ of Kentucky	6711	2/29/2000	Mohammed Mohiuddin	Ail Meigooni	Prowess		
2214	Rad. Assoc. of Sacramento-Roseville	6711	12/7/1999	David Linstadt	Ram Virudachalam	MMS-Variseed		
1863	Methodist, Indianapolis	6711	2/28/2000	Thomas Dugan	John Ken/Ron Berg/Doug Frye	MMS-Variseed		
2570	Univ of Wisc, Wausau	6711	1/24/2000	Darryl Barton	Jeff Limmer	Prowess/ProSim		
1640	Jefferson Univ	6711	2/17/2000	Adam Dicker	Frank Waterman	MMS-Variseed		
1104	Beth Israel, NY	6711	4/25/2000	Daniel Shasha	Lin Wang	MMS-Variseed		
1730	Loyola/Hines	6711	4/18/2000	Najeeb Mohideen	Nesrin Dogan	Prowess/Focus		
2406	St. Joseph's, Albuquerque	6711	12/12/2000	Paul Anthony	David Lake	Pinnacle		
2599	Univ of Maryland	6711	4/23/2001	Pradip Amin	Allen Li	Strata		
1783	Mass Gen	6711	8/3/2000	Anthony Zietman	Thomas Mauerci	MMS-Variseed		
1520	Hamilton Regional	6711	5/9/2001	J. Sathya	Orest Ostapiak	Pinnacle		
2214	Rad. Assoc. of Sacramento-Roseville	6711	6/30/2000	Seth Rosenthal	Ram Virudachalam	MMS-Variseed		
1011	Akron City	6711	12/12/2000	Michael Seider	Ashoka Bhargava	MMS-Variseed		



Radiation Therapy
Oncology Group

RTOG 0022 IMRT H&N – Oropharyngeal Credentialing Process Notification






Radiation Therapy
Oncology Group

RTOG 0225

IMRT H&N – Nasopharyngeal

Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0022 & 0225



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The IMRT Head and Neck Phantom irradiation component of the credentialing process reviewed by the Radiological Physics Center (RPC) and the testing for the dry run case through the Image-Guided Therapy Center (ITC) for RTOG 0022 – Phase I/II Study of Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer and RTOG 0225 – Phase II Study of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal Cancer has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0022 and RTOG 0225.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance



Radiation Therapy
Oncology Group

Approved Institutions RTOG – 0022 & 0225

17 Institutions Credentialed 36 Institutions in process

Institution	NCI #	RTOG Inst.#	ITC Dry Run Approval	Digital Phantom Data Submission to ITC	ITC Acceptable	RTF #	Phantom Irradiation	RPC Phantom Approval	RPC Acceptable	Status	Repeats	RPC Acceptable	Overall Approval
RTOG 0022 & 0225													
Akron City Hospital						1011							
Albuquerque Regional Medical Center	OH055	1518				2406	02/19/2003		No	Active			
California Cancer Center						1166	05/15/2002		No				
Central Wisconsin Cancer Program (St. Agnes, Wisconsin)	WI060	7013				1231	02/04/2003		No	Resign-12/31/96			
Community Medical Center	NJ070	2211				1293	01/16/2004	02/13/2004	Yes	Active			
Cross Cancer Institute	11104	7501	12/21/2001	12/21/2001	Yes	1313	07/29/2001	1st 10	Yes	Active			Yes
Emory Clinic	GA005	1523				1401		02/12/2004	No	Active			
Fairview University Medical Center	MN022	1312				2603	02/19/2004	03/17/2004	No	Active			
Flower Memorial Hospital						1440	11/02/2002		No				
Fox Chase Cancer Center	PA088	2212				1449	12/02/2002		No	Active	Repeat - 9/4/03	Yes	
Georgetown University Medical Center	DC005	5487				1471	03/28/2003		No	Resign-2/21/00			
Good Samaritan, Portland OR		2133	02/20/2003	05/07/2003	Yes	1483	04/30/2003	06/06/2003	Yes	Resign-10/1/85	Repeat - 7/25/03	Yes	Yes
H. Lee Moffitt Cancer Center	FL079	0488				1512	01/19/2004	03/02/2004	No	Active			
Holmes Regional Medical Center	FL021	2236				1557	07/17/2002		No Report	Resign-1/21/03	Repeat - 7/7/03	Yes	
Intercountry Cancer Center, Cincinnati, OH						1620	Currently have Phantom			Not a Member			
Iowa Methodist Medical Center	IA004	0200				1628	04/24/2003		No	Resign-4/15/97			
John's Hopkins	MD017	5701	04/03/2003	03/31/2003	Yes	1652	01/20/2003	06/06/2003	Yes	Active			Yes
Kansas City Cancer Centers-Southwest (CCOP)		0161				1654	02/13/2004	03/17/2004	Yes	Resign-2/1/98			
LDS Hospital	UT004	2501				1675	12/12/2003	01/15/2004	Yes	Active			
M.D. Anderson Cancer Center	TX035	5901	11/14/2001	11/14/2001	Yes	1744	04/14/2001	1st 10	Yes	Active			Yes
Massachusetts General Hospital	MA034	5801				1783	05/08/2003	1st 10	Yes	Active			
Mayo Clinic, Rochester, MN	MN026	0184				1785	05/20/2003	06/23/2003	Yes	Active			
McGill	11152	1201	03/25/2004	03/25/2004	Yes	1903	12/08/2003	02/04/2004	Yes	Active			Yes
Medical College of Wisconsin	WI013	7001	02/20/2002	02/20/2002	Yes	1460	03/09/2001	1st 10	Yes	Active			Yes
Memorial Health University Medical Center		2301				1810			No				
Memorial Sloan-Kettering Cancer Center	NY016	2301					10/31/2003	12/04/2003	Yes	Active			
Naval Medical Center Portsmouth						1941	06/16/2003	07/18/2003	Yes	Active			
Northwest Community Hospital	IL001	7705					08/20/2003	12/02/2003	Yes	Active			
Queen's Medical Center, Honolulu, Hawaii	HI004	5301				2120	02/25/2003	06/23/2003	Yes	Active			
Radiation Oncology Centers of Las Vegas	CA269	6201	05/22/2003	01/10/2003	Yes	2138	02/24/2004	03/17/2004	Yes	Active			Yes
Radiological Associates Sacramento (Sutter)	CA059	5490				2503	10/16/2003	12/05/2003	Yes	Active			Yes
Regional Radiology Oncology Center, Rome, GA	SA059	5490				1621	03/28/2003		No	Active			Yes
Saskatoon Cancer Center	11120	7512	12/10/2001	12/10/2001	Yes	2260	11/09/2001	1st 10	Yes	Active			Yes
Sentara Norfolk General Hospital						2271	11/01/2003		Yes	Active			
St Luke's Bethlehem, PA	PA054	1324				2433	06/18/2003	07/18/2003	Yes	Active			
Swedish Cancer Institute													
Thomas Jefferson University	PA121	0601	11/14/2001	11/14/2001	Yes	1640	09/28/2000	1st 10	Yes	Active			Yes
Tom Baker Cancer Centre	11134	8901	06/23/2003	06/23/2003	Yes	2535	02/24/2003	06/23/2003	Yes	Active			Yes
University Hospital of Cincinnati	OH070	2113				2589	01/22/2004	03/03/2004	Yes	Active			
University of Alabama at Birmingham	AL002	2110	06/30/2003	06/30/2003	Yes	2592	05/18/2003	06/30/2003	Yes	Active			
University of California, Davis, Sacramento, CA 95817	CA189	2423				2584	10/27/2003	12/09/2003	Yes	Active			Yes
University of California San Francisco	CA136	2401	04/10/2002			2564	02/27/2002	1st 10	Yes	Active			Yes
University of Florida, Gainesville	FL015	3228				2592	02/12/2002	1st 10	Yes	Active			
University of Michigan Medical Center	MI014	2235	06/16/2003	06/16/2003	Yes	2602	01/28/2003	06/23/2003	Yes	Active			Yes
University of Pennsylvania	PA075	2201				2610	02/19/2004	03/17/2004	Yes	Resign-12/2/03			
University of Texas Medical Branch, Galveston	TX045	6401	04/10/2002	04/10/2002	Yes	2618	02/11/2002	1st 10	Yes	Active			Yes
University of Wisconsin	WI020	0801	06/23/2003	06/23/2003	Yes	2632	05/14/2003	06/30/2003	Yes	Active			Yes
Virginia Mason Medical Center	WA054	0131				2681	Currently have Phantom		No	Active	Repeat - 7/24/03	No	
Wake Forest University School of Medicine	NC002	5483				2687	11/14/2003	02/10/2004	Yes	Active			
Washington University		2101	03/02/2004		Yes	1075	08/08/2001	1st 10	Yes	Active			Yes
Waukesha Memorial Hospital	WI051	7015				2704	06/24/2002	06/23/2003	Yes	Active			
Wilkes-Barre General Hospital	PA060	1323				2741	10/22/2002	02/06/2004	Yes	Active	Repeat - 7/13/03	Yes	
William Beaumont Hospital, Royal Oak, MI	MI005	7720	02/27/2003	05/12/2003	Yes	2744	05/07/2003	01/13/2004	Yes	Active		Yes	Yes



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

Since your institution has been credentialed for the IMRT Head and Neck protocols (RTOG 0022 & RTOG 0225) you will be automatically credentialed to participate in the Prostate protocol using IMRT (RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer). You will not be required to do additional credentialing for the use of IMRT on RTOG 0126.

You are now approved to enter patients onto RTOG Protocol 0126.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC




Radiation Therapy
Oncology Group

RTOG 0319

Breast – 3D-CRT

Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0319



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The Credentialing process and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0319 – Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0319.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Research Associate
RTOG Randomization
ITC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0319



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

Since your institution has been approved in the past for credentialing on other Advanced Technology 3D CRT Protocols, you will be automatically credentialed into RTOG 0319 – Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma, therefore, you will not be required to do additional credentialing for RTOG 0319.

You are approved to enter patients onto RTOG Protocol 0319.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Research Associate
RTOG Randomization
ITC



Radiation Therapy
Oncology Group

ATC Meeting Schedule

- Monthly teleconferences are held on the first Wednesday of each month to keep all ATC participants up to date on ongoing effects. Next call on April 7, 2004 at 2:00 CST.
- ATC meeting at the RTOG Semi-Annual Meeting in Washington, D.C., Capital Hilton, Thursday, June 24, 2004 at 8:00am – 5:00pm.



Radiation Therapy
Oncology Group

R. T. Quality Assurance Staff



Back Row L/R: Betty Martin, Bernadine Dunning, Tammy Rogers, Denise Manfredi

Front Row L/R: Julie McIlvaine, Joanne Hunter, Lorraine Quarles